ERBB2 and breast cancer: HER2 reporting criteria were originally developed as a guidance in decisions regarding standard-of-care treatment using anti-HER2 monoclonal antibodies in breast cancer, and patients are considered HER2-positive if IHC score is 3+ or FISH shows amplification (49).